Prevalence and Risk Factors for Chronic Kidney Disease in Belize: A Population-based Survey.
Belize
Central America
chronic kidney disease
health surveys
prevalence
risk factors
Journal
Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
23
04
2021
revised:
16
06
2021
accepted:
18
06
2021
entrez:
13
2
2023
pubmed:
17
7
2021
medline:
17
7
2021
Statut:
epublish
Résumé
Health resources supporting dialysis and chronic kidney disease (CKD) patients are limited in Central America, and little information about the prevalence and risk factors for CKD in this region is available. The Survey of Risk Factors for Chronic Kidney Disease was a population-based cross-sectional study conducted throughout Belize in 2017. The study aimed to assess the prevalence and risk factors for CKD via structured questionnaires and clinical measurements in Belizeans aged 20-55 years. A two-stage stratified sampling technique was applied. CKD was defined as an estimated glomerular filtration rate < 60 mL/min/1·73 m A total of 7,506 adults with a mean age of 34·6 years old completed the survey; 53·2% were women. The overall CKD prevalence was 13·7%. Women had a higher CKD prevalence than men (14·8% vs. 12·5%), and the overall awareness of CKD was low (3·7%). The prevalences of stage 1, 2, 3a, 3b, 4, and 5 CKD were 2·85%, 2·93%, 6·59%, 1·10%, 0·18%, and 0·06%, respectively. Older age, female sex, Mestizo/Hispanic ethnicity, diabetes, hypertension, hypercholesterolaemia, and obesity were identified as independent risk factors for CKD. The prevalence of CKD was 13·7% in Belizeans aged 20-55 years. The study confirms the high burden of CKD in Belize and provides important epidemiological information for Central America. Case management systems and surveillance programmes targeting high-risk populations are crucial for ameliorating the burden of CKD. Capacity Building Project for the Prevention and Control of Chronic Renal Failure in Belize.
Sections du résumé
Background
UNASSIGNED
Health resources supporting dialysis and chronic kidney disease (CKD) patients are limited in Central America, and little information about the prevalence and risk factors for CKD in this region is available.
Methods
UNASSIGNED
The Survey of Risk Factors for Chronic Kidney Disease was a population-based cross-sectional study conducted throughout Belize in 2017. The study aimed to assess the prevalence and risk factors for CKD via structured questionnaires and clinical measurements in Belizeans aged 20-55 years. A two-stage stratified sampling technique was applied. CKD was defined as an estimated glomerular filtration rate < 60 mL/min/1·73 m
Findings
UNASSIGNED
A total of 7,506 adults with a mean age of 34·6 years old completed the survey; 53·2% were women. The overall CKD prevalence was 13·7%. Women had a higher CKD prevalence than men (14·8% vs. 12·5%), and the overall awareness of CKD was low (3·7%). The prevalences of stage 1, 2, 3a, 3b, 4, and 5 CKD were 2·85%, 2·93%, 6·59%, 1·10%, 0·18%, and 0·06%, respectively. Older age, female sex, Mestizo/Hispanic ethnicity, diabetes, hypertension, hypercholesterolaemia, and obesity were identified as independent risk factors for CKD.
Interpretation
UNASSIGNED
The prevalence of CKD was 13·7% in Belizeans aged 20-55 years. The study confirms the high burden of CKD in Belize and provides important epidemiological information for Central America. Case management systems and surveillance programmes targeting high-risk populations are crucial for ameliorating the burden of CKD.
Funding
UNASSIGNED
Capacity Building Project for the Prevention and Control of Chronic Renal Failure in Belize.
Identifiants
pubmed: 36776754
doi: 10.1016/j.lana.2021.100013
pii: S2667-193X(21)00005-3
pmc: PMC9903977
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100013Informations de copyright
© 2021 The Author(s). Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Kidney Int Rep. 2017 Jun 08;2(6):1032-1041
pubmed: 29270512
N Engl J Med. 2019 May 9;380(19):1843-1852
pubmed: 31067373
Nephron. 2018;139(4):313-318
pubmed: 29791905
Am J Kidney Dis. 2017 Nov;70(5):666-674
pubmed: 28764919
Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1757-66
pubmed: 26416946
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Diabetes Care. 2012 Apr;35(4):738-40
pubmed: 22323417
Kidney Int. 2011 Mar;79(5):555-62
pubmed: 21107446
JAMA. 2019 Oct 1;322(13):1294-1304
pubmed: 31573641
Lancet. 2018 Nov 10;392(10159):2052-2090
pubmed: 30340847
Am J Kidney Dis. 2014 May;63(5):713-35
pubmed: 24647050
J Epidemiol Community Health. 2018 Apr;72(4):280-286
pubmed: 29437864
Lancet Glob Health. 2016 May;4(5):e307-19
pubmed: 27102194
Nefrologia. 2014;34(5):591-8
pubmed: 25259814
Kidney Int. 2015 Nov;88(5):950-7
pubmed: 26221752
J Am Soc Nephrol. 2020 Jul;31(7):1585-1593
pubmed: 32471819
JAMA Intern Med. 2017 Jun 1;177(6):792-799
pubmed: 28288249
MEDICC Rev. 2014 Apr;16(2):23-30
pubmed: 24878646
MEDICC Rev. 2019 Apr-Jul;21(2-3):29-37
pubmed: 31373582
Eur J Epidemiol. 2007;22(12):899-906
pubmed: 17926136
Am J Kidney Dis. 2019 Jan;73(1):102-111
pubmed: 29661541
Can J Kidney Health Dis. 2015 Feb 24;2:6
pubmed: 25926994
Am J Kidney Dis. 2014 Mar;63(3):506-20
pubmed: 24412050
Lancet. 2011 Oct 1;378(9798):1244-53
pubmed: 21846575
Nat Rev Nephrol. 2018 Mar;14(3):151-164
pubmed: 29355169
Circulation. 2014 Jun 24;129(25 Suppl 2):S102-38
pubmed: 24222017
Adv Chronic Kidney Dis. 2010 Jul;17(4):302-7
pubmed: 20610357
Am J Kidney Dis. 2010 Mar;55(3):485-96
pubmed: 20116154
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
JAMA Intern Med. 2014 Jul;174(7):1108-15
pubmed: 24798807
Nephrol Dial Transplant. 2011 Sep;26(9):2798-805
pubmed: 20615905
Lancet Glob Health. 2014 Aug;2(8):e440-1
pubmed: 25103508
Rev Panam Salud Publica. 2015 Sep;38(3):202-8
pubmed: 26757998
Nephrol Dial Transplant. 2016 Jun;31(6):868-74
pubmed: 27217391
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169